Business Insider

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting | Markets Insider

- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients ...
Benzinga.com

Adverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal Study

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...
Seeking Alpha

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Hello, ladies and gentlemen. Thank you for standing by, and welcome to the Adverum's Webcast to discuss the 26-Week Interim Analysis of the ongoing LUNA Phase 2 trial that was presented earlier today ...
Nasdaq

Adverum Reports Positive Ixo-vec Data From Interim Analysis Of LUNA Phase 2 Trial

(RTTNews) - Adverum Biotechnologies (ADVM) reported results from the 26-week interim analysis of the LUNA Phase 2 trial of Ixo-vec in patients with wet age-related macular degeneration. Adverum said ...